At the time of this piece, only three therapies targeting mutant p53 have reached phase III clinical trials: the structural reactivators APR-256 and COTI-2 to treat mutant p53 myelodysplastic syndrome, and the MDM2 inhibitor RG7388 or idasanutlin for refractory acute myeloid leukemia (Montesinos et al., 2020; Sallman et al., 2018). The gene discussed is TP53; the disease is myelodysplastic syndrome.